Whole-Brain Atrophy as a Measure of Progression in Premanifest and Early Huntington's Disease
Whole-Brain Atrophy as a Measure of Progression in Premanifest and Early Huntington's Disease
复制标题
DOI：
10.1002/mds.22485
复制
发表时间：
2009-04-30
影响因子：
8.6
通讯作者：
Tabrizi, Sarah J.
中科院分区：
文献类型：
--
作者：
Henley, Susie M. D.;Wild, Edward J.;Tabrizi, Sarah J.
亨廷顿病（HD）的治疗试验具有挑战性，因为临床进展缓慢，缺乏可变和可靠的生物标志物。我们使用磁共振成像和脑边界移位积分来量化早期和预表现HD受试者和对照组1年内的全脑萎缩率。与对照组相比，早期HD受试者的全脑萎缩率在统计学上显著增加（P = 0.007）（高出3倍）。萎缩率较高与CAG重复长度较长相关。基于MRI的全脑萎缩指标可能作为HD进展的指标。(C)2009运动障碍协会
Therapeutic trials in Huntington's disease (HD) are challenging as clinical progression is slow and variable and reliable biomarkers are lacking. We used magnetic resonance imaging and the brain boundary shift integral to quantify whole-brain atrophy rates over 1 year in early and premanifest HD subjects, and controls. Early HD subjects had statistically significantly (P = 0.007) increased (threefold higher) rates of whole-brain atrophy compared with controls. Higher atrophy rates were associated with longer CAG repeat length. MRI-based measures of whole-brain atrophy may have potential as a measure of progression in HD. (C) 2009 Movement Disorder Society